{
    "data": [
        {
            "id": "4653985",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-24T04:34:34-05:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1424217301/image_1424217301.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Stock Is Dirt Cheap And Worth Buying",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105995",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "504331",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653985-viatris-stock-q3-earnings-cheap-worth-buying"
            }
        },
        {
            "id": "4653463",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-21T13:48:38-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/465389483/image_465389483.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: It Is Always Cheap, Yet It Is Always Declining",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503723",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653463-viatris-it-is-always-cheap-yet-it-is-always-declining"
            }
        },
        {
            "id": "4642069",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-20T10:00:29-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132050/image_1359132050.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Get Paid 5%, Before Growth Materializes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494727",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642069-viatris-get-paid-5-percent-before-growth-materializes"
            }
        },
        {
            "id": "4642064",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-20T03:02:47-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/83803495/image_83803495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris' Survival Guide: Strategic Divestitures And Margins",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494930",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642064-viatris-survival-guide-strategic-divestitures-and-margins"
            }
        },
        {
            "id": "4638174",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-29T15:00:25-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468540296/image_1468540296.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "489774",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4638174-viatris-generic-semaglutide-become-poor-mans-option-for-weight-loss"
            }
        },
        {
            "id": "4635110",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-14T06:07:30-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479719862/image_1479719862.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why 5%-Yielding Viatris Hasn't Doubled Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "485600",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635110-why-5-percent-yielding-viatris-hasnt-doubled-yet"
            }
        },
        {
            "id": "4629614",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-18T13:09:45-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399395748/image_1399395748.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "479317",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4629614-viatris-challenger-in-lucrative-anti-obesity-drugs-market"
            }
        },
        {
            "id": "4627267",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-11T04:04:38-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465073112/image_1465073112.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Turning Point For Cheap Pharma Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106648",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477174",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4627267-viatris-q2-2023-earnings-turning-point-cheap-pharma-stock-reiterate-buy"
            }
        },
        {
            "id": "4625311",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-08T10:34:31-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Q2 2023 Earnings Review: Buy, Sell, Or Hold After Mixed Results?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "476690",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4625311-viatris-q2-2023-earnings-review-buy-sell-or-hold-after-mixed-results"
            }
        },
        {
            "id": "4617788",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-18T10:47:52-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400025882/image_1400025882.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Currently Appealing Only To Income-Focused Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617788-viatris-currently-appealing-only-to-income-focused-investors"
            }
        },
        {
            "id": "4617671",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-18T00:28:43-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1423366794/image_1423366794.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Developing Into A Fantastic Investment Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107058",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471252",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617671-viatris-inc-developing-into-fantastic-investment-opportunity"
            }
        },
        {
            "id": "4612451",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-20T05:53:32-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405788565/image_1405788565.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Despite Its Valuation, Viatris Is Still A Hold",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "464783",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4612451-despite-its-valuation-viatris-stock-reiterate-hold"
            }
        },
        {
            "id": "4611760",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-15T12:37:07-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411224388/image_1411224388.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Won't Take Much To Move The Needle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "463678",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611760-viatris-will-not-take-much-to-move-needle"
            }
        },
        {
            "id": "4601518",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-08T10:57:48-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387162222/image_1387162222.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: That Free Cash Flow Is Not As Attractive As It Sounds",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454802",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4601518-viatris-free-cash-flow-not-as-attractive"
            }
        },
        {
            "id": "4601512",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-08T10:31:29-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391441819/image_1391441819.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris Q1: Okay But Not Great",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454801",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4601512-viatris-q1-okay-but-not-great"
            }
        },
        {
            "id": "4594276",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-16T04:01:11-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184107195/image_184107195.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris - Time To Cut This Business Some Slack?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450073",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594276-viatris-time-to-cut-this-business-some-slack"
            }
        },
        {
            "id": "4590130",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-26T18:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/181900539/image_181900539.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: The Value And The Value Trap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "446155",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4590130-viatris-the-value-and-the-value-trap"
            }
        },
        {
            "id": "4583180",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-01T08:05:00-05:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Too Cheap To Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "441051",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4583180-viatris-stock-too-cheap-to-ignore"
            }
        },
        {
            "id": "4580722",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-22T13:45:03-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344289626/image_1344289626.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect From Viatris In 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "439599",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4580722-what-to-expect-from-viatris-in-2023"
            }
        },
        {
            "id": "4577773",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-13T09:27:36-05:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/679524590/image_679524590.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Buy Viatris And Organon Just Because Of The Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "437486",
                            "type": "sentiment"
                        },
                        {
                            "id": "437487",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4577773-viatris-organon-stocks-dont-buy-dividends"
            }
        },
        {
            "id": "4571547",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-23T02:46:44-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363129327/image_1363129327.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Viatris: Where Is The Cure?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432864",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4571547-viatris-where-is-the-cure"
            }
        }
    ]
}